Biotech Startup SynFlora Unveils Novel Skin Treatment Technology at 4YFN Trade Show
“We are creating a base of a new skin product…it’s really like a molecular machine.” – Co-founder and CEO Nastassia Knōdlseder
The biotech startup SynFlora took the stage at the MWC tradeshow in Barcelona this week, bringing with them an enticing pitch for a revolutionary type of skin treatment technology. The Spanish company, founded by three PhD-holders, is dedicated to enhancing our understanding of the skin’s microbiome and utilizing engineered skin microbes to develop targeted and innovative therapeutics.
Their concept goes beyond the surface level application of creams, commonly seen in current “active” skincare products. Instead, they aim to harness biotechnology methods to deliver treatments at a deeper level, using bacteria as a vehicle for targeted therapeutics.
- Their early research is primarily focused on treating acne.
- They recently published a paper on their experimental treatment delivery approach in the journal Nature Biotechnology.
- Their method involves using a “sebum modulator” in an engineered skin microbe on mice.
While acne is their initial target, the possibilities for their technology extend far beyond skincare. Co-founder and CEO Nastassia Knōdlseder envisions potential uses such as mosquito repellant, fat loss (a cream for cellulite, anyone?), and even vaccines and anti-inflammatory treatments.
“We have the potential…to create vaccines against melanoma, for example…and the production of anti-inflammatory molecules.” – Co-founder and CEO Nastassia Knōdlseder
This versatile platform has already sparked interest in multiple industries, leading the team to secure patents for different indications of the technology and for the platform itself. Knōdlseder emphasizes that they have no intention of limiting themselves to a single use-case.
Early Stage Startup with Big Plans
While SynFlora is still in its early stages, with a current focus on raising a seed round, the team is optimistic about the future. Knōdlseder believes they could be anywhere from one to three years away from seeing their novel system in action, powering a new generation of skin-delivered therapeutics.
Of course, the company will have to meet regulatory standards for safety and efficacy before their technology will be able to reach consumers. However, with their innovative approach and ambitious goals, SynFlora has the potential for major impact on the biotech and skincare industries.
